1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine dihydrochloride

Catalog No. :
ACRAXE401
CAS No. :
2173992-01-1
Molecular Formula :
C5H10Cl2N4S
Molecular Weight :
229.14

IUPAC Name:1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine dihydrochloride

1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$107.00Login to see priceInquiryInquiry
250mg97%$145.00Login to see priceInquiryInquiry
500mg97%$241.00Login to see priceInquiryInquiry
1g97%$361.00Login to see priceInquiryInquiry
5g97%$1081.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine dihydrochloride
IUPAC Name1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine dihydrochloride
MDL No.MFCD31617918
Molecular FormulaC5H10Cl2N4S
Molecular Weight229.14
SMILESNC1CN(C2=NN=CS2)C1.[H]Cl.[H]Cl
InChI KeyGRURSWRPQBZMRZ-UHFFFAOYSA-N
Synonym1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine dihydrochloride | 2173992-01-1 | 1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine 2hcl | 1-(1,3,4-thiadiazol-2-yl)azetidin-3-amine | dihydrochloride | 1343676-60-7 | AMY35799 | MFCD31617918 | AKOS037644725 | SB40979 | AS
CAS No.2173992-01-1
PubChem CID134129819

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACRAXE401 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRAXE401 route product structure diagram
    ACRAXE4012173992-01-1
Inquiry

2. ACRAXE401 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRAXE401 route product structure diagram
    ACRAXE4012173992-01-1
Inquiry

Comments (0)